The following represents MIC susceptibility data for a few medically significant bacteria:
Haemophilus influenzae: 0.015 to 256 μg/ml
Staphylococcus aureus: 0.023 to 1024 μg/ml
Streptococcus pyogenes: 0.004 to 256 μg/ml
Corynebacterium minutissimum: 0.015 to 64 μg/mlIt may be useful in treating gastroparesis due to this promotility effect. It has been shown to improve feeding intolerances in those who are critically ill. Intravenous erythromycin may also be used in endoscopy to help clear stomach contents. Available forms
Erythromycin is available in enteric-coated tablets, slow-release capsules, oral suspensions, ophthalmic solutions, ointments, gels, enteric-coated capsules, non enteric-coated tablets, non enteric-coated capsules, and injections. The following erythromycin combinations are available for oral dosage:
erythromycin base (capsules, tablets)
erythromycin estolate (capsules, oral suspension, tablets),  contraindicated during pregnancy
erythromycin ethylsuccinate (oral suspension, tablets)
erythromycin stearate (oral suspension, tablets)For injection, the available combinations are:
erythromycin gluceptate
erythromycin lactobionateFor ophthalmic use:

erythromycin base (ointment)

Adverse effects
Gastrointestinal disturbances, such as diarrhea, nausea, abdominal pain, and vomiting, are very common because erythromycin is a motilin agonist. Because of this, erythromycin tends not to be prescribed as a first-line drug. More serious side effects include arrhythmia with prolonged QT intervals, including torsades de pointes, and reversible deafness. Allergic reactions range from urticaria to anaphylaxis. Cholestasis, Stevens–Johnson syndrome, and toxic epidermal necrolysis are some other rare side effects that may occur. Studies have shown evidence both for and against the association of pyloric stenosis and exposure to erythromycin prenatally and postnatally. Exposure to erythromycin (especially long courses at antimicrobial doses, and also through breastfeeding) has been linked to an increased probability of pyloric stenosis in young infants.
Uterine tachysystole is a condition of excessively frequent uterine contractions during pregnancy. It is most often seen in induced or augmented labor, though it can also occur during spontaneous labor.Because contraction counts are often measured over periods of ten minutes but averaged over periods of thirty minutes, there can be slight differences in how the cutoff is calculated. Generally it is defined as more frequently than once every two minutes. Although definitions may vary among studies, most use the terms defined by the American Congress of Obstetricians and Gynecologists (1999a) to describe increased uterine activity as follows:

Uterine tachysystole is defined as  more than 5 contractions in 10 minutes, averaged over a 30-minute window. Uterine hypertonus is described as a single contraction lasting longer than 2 minutes. Uterine hyperstimulation is when either condition leads to a nonreassuring fetal heart rate pattern.The American Congress of Obstetricians and Gynecologists amended these definitions in 2008. Uterine tachysystole is defined as more than 5 contractions in 10 minutes, averaged over a 30-minute period. The terms "hypertonus" and "hyperstimulation" are not recommended to be used. Uterine tachysystole has been reported to follow vaginally administered Prostaglandin E2 in 1 to 5 percent of women (Brindley and Sokol, 1988; Rayburn, 1989). It can be associated with placental abruption and perhaps with uterine leiomyomas. It can also refer to hyperstimulation with oxytocin. == References ==